Wägner AM - Search Results

1

Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C Plus assay?

Ordóñez-Llanos J, Wägner AM, Bonet-Marqués R, Sánchez-Quesada JL, Blanco-Vaca F, González-Sastre F. Ordóñez-Llanos J, et al. Among authors: wagner am. Clin Chem. 2001 Jan;47(1):124-6. Clin Chem. 2001. PMID: 11148187 No abstract available.

2

The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients.

Wägner AM, Zapico E, Bonet R, Pérez A, Ordóñez-Llanos J. Wägner AM, et al. Clin Biochem. 2003 May;36(3):177-83. doi: 10.1016/s0009-9120(03)00006-7. Clin Biochem. 2003. PMID: 12726925

3

Inaccuracy of calculated LDL-cholesterol in type 2 diabetes: consequences for patient risk classification and therapeutic decisions.

Wägner AM, Sánchez-Quesada JL, Pérez A, Rigla M, Cortés M, Blanco-Vaca F, Ordóñez-Llanos J. Wägner AM, et al. Clin Chem. 2000 Nov;46(11):1830-2. Clin Chem. 2000. PMID: 11067819 No abstract available.

4

Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion.

Wägner AM, Ordóñez-Llanos J, Arcelus R, Bonet R, Jorba O, Sánchez-Quesada JL, Alonso E, Julve J, Pérez A. Wägner AM, et al. Metabolism. 2003 Aug;52(8):1038-42. doi: 10.1016/s0026-0495(03)00090-8. Metabolism. 2003. PMID: 12898470 Clinical Trial.

5

Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients.

Wägner AM, Pérez A, Zapico E, Ordóñez-Llanos J. Wägner AM, et al. Diabetes Care. 2003 Jul;26(7):2048-51. doi: 10.2337/diacare.26.7.2048. Diabetes Care. 2003. PMID: 12832311

6

LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes.

Wägner AM, Jorba O, Rigla M, Alonso E, Ordóñez-Llanos J, Pérez A. Wägner AM, et al. Acta Diabetol. 2002 Dec;39(4):215-20. doi: 10.1007/s005920200037. Acta Diabetol. 2002. PMID: 12486496

7

Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes.

Wägner AM, Jorba O, Rigla M, Bonet R, de Leiva A, Ordóñez-Llanos J, Pérez A. Wägner AM, et al. Metabolism. 2003 Dec;52(12):1576-8. doi: 10.1016/s0026-0495(03)00326-3. Metabolism. 2003. PMID: 14669158 Clinical Trial.

8

Triglyceride-to-HDL cholesterol ratio in the dyslipidemic classification of type 2 diabetes.

Wägner AM, Pérez A, Sánchez-Quesada JL, Ordóñez-Llanos J. Wägner AM, et al. Diabetes Care. 2005 Jul;28(7):1798-800. doi: 10.2337/diacare.28.7.1798. Diabetes Care. 2005. PMID: 15983340 No abstract available.

9

Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.

Wägner AM, Sánchez-Quesada JL, Benítez S, Bancells C, Ordóñez-Llanos J, Pérez A. Wägner AM, et al. Diabetes Res Clin Pract. 2011 Jul;93(1):e25-8. doi: 10.1016/j.diabres.2011.03.009. Epub 2011 Mar 26. Diabetes Res Clin Pract. 2011. PMID: 21440948 Clinical Trial.

10

Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control.

Pérez A, Wägner AM, Carreras G, Giménez G, Sánchez-Quesada JL, Rigla M, Gómez-Gerique JA, Pou JM, de Leiva A. Pérez A, et al. Among authors: wagner am. Arch Intern Med. 2000 Oct 9;160(18):2756-62. doi: 10.1001/archinte.160.18.2756. Arch Intern Med. 2000. PMID: 11025785

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters